{"filings":[{"id":746717,"accession_number":"0001193125-26-248289","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2026-05-29T20:10:56+00:00","items":["5.02"],"status":"ready","headline":"Benitec Biopharma appoints David Friedman to board; Megan Boston resigns as director but remains CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Friedman joined board as Class III director effective May 22, 2026; term until 2028 annual meeting.","Friedman granted options to purchase 35,000 shares at closing price on May 26, 2026; vesting by next annual meeting or 1 year.","Megan Boston resigned from board effective May 22, 2026; continues as CFO and secretary; no dispute.","Friedman entitled to standard non-employee director compensation; will enter indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77961,"accession_number":"0001193125-26-222879","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2026-05-14T12:09:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Q3 net loss $0.24/shr, cash $184.8M; BB-301 clinical progress continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.9M ($0.24/shr) vs $14.5M ($0.38/shr) in prior year quarter; total expenses $13.6M.","Cash and equivalents $184.8M, well-capitalized to advance BB-301 through pivotal study.","Cohort 1 low-dose BB-301 shows durable responses at 12-24 months; Cohort 2 high dose safely treating patients.","Oral presentation at ASGCT 2026 on May 15; FDA engagement mid-year to formalize pivotal study design.","Updated BB-301 interim results expected 2H-2026; no treatment-related severe adverse events observed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108850,"accession_number":"0001193125-26-047742","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Q2 FY2026 net loss $11.8M; all Cohort 1 patients respond to BB-301 at 12 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.8M ($0.26 per share) vs $9.6M YoY; total expenses $13.4M (up from $10.8M).","All 4 Cohort 1 completers in BB-301 Phase 1b/2a met Responder criteria at 12-month follow-up.","Patient 1 showed deepening improvements in swallow function and dysphagia at 24 months.","Cash and equivalents $189M; FDA meeting mid-2026 to confirm pivotal study design for BB-301.","Cohort 2 interim results expected mid-2026; first patient dosed in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125312,"accession_number":"0001193125-25-305475","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Benitec Biopharma stockholders elect directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["22,327,761 shares present (85.06% of outstanding); all proposals passed.","Directors Dr. Jerel Banks (22,150,169 for) and Megan Boston (21,693,741 for) elected.","Ratification of independent auditor approved: 22,252,834 for, 4,787 against.","Advisory vote on executive compensation passed with 17,239,339 for, 4,939,686 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125311,"accession_number":"0001193125-25-283351","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Q1 net loss $9.0M; BB-301 100% responder rate; FDA Fast Track; raised $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.0M ($0.22/sh) vs $5.1M ($0.18) YoY; total expenses $9.8M, up from $5.8M.","All 6 Cohort 1 patients in BB-301 Phase 1b/2a met formal response criteria (100% responder rate).","FDA granted Fast Track Designation for BB-301; first Cohort 2 patient dosed in Q4 2025.","Raised ~$100M in oversubscribed equity offering at $13.50/sh; cash $94.5M at Sep 30.","Appointed Sharon Mates (ex-CEO Intra-Cellular Therapies) to Board of Directors."],"consensus_eps_estimate":-0.2791,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125310,"accession_number":"0001193125-25-270490","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Benitec Biopharma prices $100M equity offering at $13.50/share (7.4M shares total)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 5,930,000 shares plus 889,500-share underwriter option; concurrent registered direct offering of 1,481,481 shares to Suvretta Capital affiliates.","Gross proceeds ~$100M; net proceeds to fund product candidate programs, working capital, and general corporate purposes.","Offerings priced at $13.50 per share; expected to close Nov 7, 2025 subject to customary conditions.","Company, execs, directors, and Suvretta Capital subject to 90-day lock-up on share sales after Nov 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125309,"accession_number":"0001193125-25-261665","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Benitec gets FDA Fast Track for BB-301 in OPMD; 100% response rate in Cohort 1","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation to BB-301 for OPMD with dysphagia; BB-301 also has Orphan Drug Designation from FDA and EMA.","All six Cohort 1 patients met statistical response criteria (100% response rate) with significant improvements in dysphagia measures.","First Cohort 2 patient treated in Q4 2025; Benitec plans FDA meeting in 2026 to confirm pivotal study design.","Appointed Dr. Sharon Mates to board; she was co-founder/CEO of Intra-Cellular Therapies (acquired by JNJ for ~$14.6B in 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142028,"accession_number":"0001193125-25-211462","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Biopharma FY2025 net loss $37.9M ($1.05/sh); BB-301 DSMB clears Cohort 2 enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.9M ($1.05/share) vs $22.4M ($1.22/share) in FY2024; total expenses $41.8M (up 86%).","R&D expense $18.3M (up 17%) on BB-301 clinical development; G&A $23.4M (up 235%) driven by stock-based comp $14.5M.","Cash and equivalents $97.7M (up from $50.9M) after equity offerings.","DSMB recommended continuation; Cohort 2 enrollment and interim Cohort 1 data both expected Q4 2025.","BB-301 Phase 1b/2a for OPMD with dysphagia; no revenue reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142027,"accession_number":"0000950170-25-114530","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Benitec restates Q2 and Q3 FY2025 financials for stock-comp understatement; prior filings unreliable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee concluded Dec 31, 2024 and Mar 31, 2025 unaudited financials should no longer be relied upon.","Error from November 2023 system migration incorrectly configured equity awards data, understating share-based compensation.","Non-cash adjustments understated additional paid-in capital, accumulated deficit, net loss, and loss per share.","Restated financials to be included in FY2025 Form 10-K, expected to be filed on or before the deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142026,"accession_number":"0001193125-25-157095","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Benitec Biopharma reports DSMB recommends continuation of BB-301 Phase 1b/2a study after Cohort 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sixth and final subject of Cohort 1 safely treated with low dose of BB-301 in April 2025.","Independent DSMB reviewed all six Cohort 1 subjects and recommended continuation of enrollment.","Enrollment of Cohort 2 expected to begin in Q4 2025 following positive DSMB recommendation.","Additional clinical study updates for Cohort 1 subjects planned for Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159996,"accession_number":"0001193125-25-119402","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Biopharma reports Q3 FY2025 net loss of $9.4M; cash $103.6M; BB-301 low-dose cohort completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.4M ($0.24/share) vs $4.3M ($0.23/share) in prior year; expenses rose to $10.2M on higher R&D and G&A.","Cash and cash equivalents $103.6M as of March 31, 2025, up from $50.9M at June 30, 2024.","BB-301: sixth and final subject in Cohort 1 (low dose) treated safely in April 2025; enrollment at higher dose expected later this year.","Additional clinical study updates for Cohort 1 subjects planned for Q4 calendar 2025."],"consensus_eps_estimate":-0.3757,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178323,"accession_number":"0001193125-25-067232","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Benitec Biopharma closes ~$30.5M equity offering; issues 2.043M shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$30.5M from underwritten offering of 1.143M shares + 300K pre-funded warrants at $13.00/$12.999 per share.","Direct offering to Averill Master Fund and Averill Madison Master Fund of 900K shares at $13.00 per share.","Post-closing: 25,546,288 common shares outstanding; warrants for 5,876,866 common shares and 15,270,807 pre-funded warrants.","Pre-funded warrants have exercise price of $0.0001 per share.","All securities sold in concurrent offerings at same price of $13.00 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178322,"accession_number":"0001193125-25-065613","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Benitec Biopharma enters registration rights agreement with Averill funds related to direct offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registration Rights Agreement with Averill Master Fund and Averill Madison Master Fund dated March 26, 2025.","Company must file resale registration statement for shares sold in direct offering within 60 days of closing.","Company must use best efforts to have registration declared effective by 90th day (120th if full SEC review).","Agreement provides customary indemnification obligations between company and purchasers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178321,"accession_number":"0001193125-25-063235","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Benitec Biopharma raises ~$30M in underwritten and direct common stock offering at $13/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 1,143,000 shares and 300,000 pre-funded warrants at $13.00/$12.9999 per unit.","Concurrent registered direct offering of 900,000 shares to Averill funds (Suvretta affiliates) at same $13.00 price.","Gross proceeds ~$30M; net proceeds to fund product candidate development, working capital, and general corporate purposes.","Benitec discussed appointing David Friedman, managing director at Suvretta Capital, to the board, subject to approval.","Offering expected to close March 26, 2025; underwriters include Leerink Partners and TD Cowen as bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178320,"accession_number":"0001193125-25-059398","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Benitec reports durable improvements in swallowing function with BB-301 in OPMD interim results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three subjects treated with low-dose BB-301 showed significant, clinically meaningful improvements in swallowing function at 12 months (Subjects 1,2) and 3 months (Subject 3) post-treatment.","Subject 1: 41% reduction in SSQ total symptom burden at 12 months; VFSS showed reductions in pharyngeal residue across all food and liquid consistencies.","Subjects 2 and 3: near-complete resolution of pathologic sequential swallows; Subject 2 achieved clinically normal SSQ (68 units) at 12 months, Subject 3 at 3 months (70 units).","No severe adverse events reported; five subjects safely treated; sixth and final Cohort 1 subject expected to receive low-dose BB-301 in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178319,"accession_number":"0001193125-25-057153","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Benitec reports positive Phase 1b/2a BB-301 data; three OPMD subjects show durable swallowing improvements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subject 1: 41% reduction in total dysphagic symptom burden (SSQ) 12-months post-treatment; VFSS improvements across consistencies.","Subject 2: 91% reduction in SSQ to 68 units (clinically normal) at 12 months; pathologic sequential swallows dropped from 80% to 17%.","Subject 3: 68% reduction in SSQ to 70 units (clinically normal) at 3 months; zero pathologic sequential swallows observed.","No severe adverse events reported; sixth and final Cohort 1 subject expected to receive low-dose BB-301 in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178318,"accession_number":"0001193125-25-026659","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Biopharma reports Q2 FY2025 net loss of $7.4M, cash at $78.3M; five patients treated with BB-301 in Phase 1b/2a","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.4M ($0.33/sh) vs $6.8M ($2.64/sh) year ago; basic shares rose from 2.6M to 22.1M on warrant exercises.","Cash and equivalents $78.3M at Dec 31, 2024, up from $50.9M; includes $39.5M from warrant exercises.","G&A expenses $3.5M (up from $1.8M); R&D flat at $5.1M; total operating expenses $8.6M.","Fifth subject safely treated with low-dose BB-301 in OPMD study; sixth subject expected in Q2 2025.","Interim clinical data to be presented in late-breaking oral at MDA conference on March 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194979,"accession_number":"0001193125-24-287065","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K/A","filed_at":"2024-12-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Benitec Biopharma grants COO Sophie Mukadam 300,000 options at $12.00","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sophie Mukadam appointed COO effective Jan 1, 2025; receives 300,000 nonqualified stock options.","Exercise price $12.00 per share, equal to closing price on grant date Dec 27, 2024.","Vesting in 16 equal quarterly installments starting Mar 31, 2025, conditioned on continued service.","Unvested options fully accelerate upon a Change in Control as defined in the Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194987,"accession_number":"0001193125-24-278529","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Benitec appoints Sophie Mukadam as COO, Megan Boston as CFO; grants stock options to executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sophie Mukadam appointed COO effective Jan 1, 2025; base salary $500K, target bonus 40%.","Megan Boston confirmed as Secretary and CFO effective Jan 1, 2025; continues as principal financial/accounting officer.","CEO Jerel Banks granted options for 2.31M shares at $12.18, vesting quarterly over four years.","CFO Megan Boston granted options for 720K shares at same price/vesting schedule.","Base salaries increased: CEO to $667K, CFO to $415K, effective Jan 1, 2025; target bonuses 55% and 40%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194986,"accession_number":"0001193125-24-274395","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Benitec Biopharma authorizes 5M shares of preferred stock, effective Dec 9, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved at Dec 4, 2024 annual meeting; amendment effective Dec 9, 2024.","Authorizes 5,000,000 shares of preferred stock, par value $0.0001, and corresponding increase in capital stock.","Amendment filed with Delaware Secretary of State; copy attached as Exhibit 3.1.","No specific use of proceeds or plan for issuance disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194985,"accession_number":"0001193125-24-272533","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Benitec Biopharma stockholders elect directors and approve preferred stock authorization at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors J. Kevin Buchi and Peter Francis elected with 17.3M and 16.5M votes respectively.","Ratification of independent auditor passed with 17,978,704 votes for, 260 against.","Advisory vote on executive compensation approved with 17,307,680 votes for.","Amendment to authorize up to 5,000,000 shares of preferred stock approved with 15,313,718 votes for (85% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194984,"accession_number":"0001193125-24-258694","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec reports Q1 FY2025 net loss $5.1M; positive clinical data for BB-301 in OPMD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.1M ($0.48/sh) vs $5.9M ($3.05/sh) prior year; cash $67.8M.","R&D expenses $3.6M, G&A $2.2M; loss from operations $5.8M.","Subject 1 had 35% SSQ Total Score improvement at Day 270; Subject 2 normal swallowing profile at Day 180.","Third subject safely treated with low-dose BB-301 in Oct 2024; fourth expected Dec 2024.","No serious adverse events observed for treated subjects."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194983,"accession_number":"0001193125-24-258668","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Benitec Biopharma approves $360k CEO bonus, $162k Exec Director bonus for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved discretionary bonus of $360,360 for CEO Jerel Banks for FY ending June 30, 2024.","Executive Director Megan Boston received a bonus of $161,580 (converted from AUD at ~0.67 USD/AUD).","Bonuses were approved on November 7, 2024, and reflect performance during fiscal year 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194982,"accession_number":"0001193125-24-237227","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Benitec reports positive interim data from BB-301 Phase 1b/2a: swallowing improvements in two OPMD subjects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subject 1 at Day 270: 35% SSQ Total Score reduction, 33% VFSS TPR reduction for thin liquids.","Subject 2 at Day 180: 89% SSQ Total Score reduction (score 82, clinically normal swallowing), 92% reduction in low-volume sequential swallows.","No Significant Adverse Events observed with low-dose BB-301 (1.2e13 vg/subject).","Third subject to be dosed this month; higher-dose cohorts enrollment expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194981,"accession_number":"0001193125-24-236782","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Benitec Biopharma enters ATM sales agreement for up to $75 million common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $75M in common stock may be sold at-the-market through agent Leerink Partners.","Agent commission of 3.0% of gross proceeds; Company to reimburse certain expenses.","Net proceeds to fund product candidate development, working capital, and general corporate purposes.","Sales under existing shelf registration statement (S-3) filed March 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194980,"accession_number":"0001193125-24-234458","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Benitec Biopharma gets ~$21.1M from Suvretta warrant exercise; shares outstanding rise to 17.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Suvretta Capital waived 19.99% beneficial ownership limit on warrants; new cap set at 49.9%.","Exercised 588,236 Series 2 warrants at $1.9299, 5,181,347 warrants at $3.86, and 1,368,180 pre-funded warrants at $0.0001.","Issued total 7,137,763 shares to Suvretta funds for aggregate proceeds of ~$21.1 million.","Outstanding common stock increased to 17,893,765 as of Oct 8, 2024, from ~10.6 million prior."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211274,"accession_number":"0001193125-24-226999","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Biopharma FY2024 net loss $22.4M, cash $50.9M; BB-301 shows swallowing improvement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.4M ($5.51 per share) for FY2024; cash and equivalents $50.9M as of June 30, 2024.","Oversubscribed $40M PIPE closed April 2024; cash runway extended through 2025.","Interim data for first low-dose BB-301 subject showed clinically meaningful improvements in swallowing at 90 and 180 days; no SAEs.","Second subject dosed Feb 2024; third subject expected Q4 2024.","Kishen Mehta appointed to board effective June 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211273,"accession_number":"0001193125-24-213348","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Benitec stockholders approve Nasdaq-related proposal and equity plan amendment at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5,947,860 shares (58.97% of outstanding) present at August 29 special meeting.","Proposal 1 (Nasdaq) approved: 5,868,978 for, 13,614 against, 168 abstain.","Proposal 2 (amendment to 2020 Equity Plan) approved: 5,024,173 for, 232,406 against, 626,181 abstain.","Adjournment proposal not presented due to sufficient votes for other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211272,"accession_number":"0001193125-24-179108","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Benitec reports durable swallowing improvements at 180 days for first BB-301 subject in Phase 1b/2a","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Post-dose Total Pharyngeal Residue meaningfully reduced at 180 days vs pre-dose average for Subject 1.","For 3 of 4 food types, TPR at 180 days lower than any point in 9-month natural history study; fourth similar to lowest.","SSQ Total Score at 180 days lower than any point in 9-month pre-dose period, indicating improved swallowing.","No SAEs observed; transient Grade 2 GERD previously reported.","Second subject dosed Feb 2024; third expected Q3 2024; additional interim data in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211271,"accession_number":"0001193125-24-173338","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Benitec appoints Kishen Mehta to board; Suvretta Capital portfolio manager","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed as Class I director effective June 26, 2024, term through 2026 annual meeting.","Mehta is portfolio manager at Suvretta Capital, which led $40M PIPE financing in April 2024.","Will serve on Nominating and Corporate Governance Committee; board deemed him independent.","Also serves on Biohaven Pharmaceuticals board; 15+ years healthcare investing experience.","Appointment follows Board Designation Agreement with Suvretta disclosed in prior 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229832,"accession_number":"0001193125-24-136730","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec reports Q3 net loss $4.3M, positive OPMD data, $40M PIPE closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.3M ($1.64 EPS) vs $4.4M ($2.67 EPS) in Q3 2023; revenue $0.","Cash $14.1M at Mar 31; subsequent $40M oversubscribed PIPE closed Apr 22 extends runway through 2025.","First OPMD subject showed clinically meaningful improvements in swallowing at 90 days post BB-301 dose; no SAEs.","Second subject dosed safely; third expected June 2024; 23 subjects enrolled in natural history study.","Additional interim safety/efficacy data expected H2 2024; Suvretta Capital led PIPE."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229831,"accession_number":"0001193125-24-101289","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Benitec Biopharma raises $40M in oversubscribed PIPE financing at $4.80/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $40M from sale of 5,749,152 shares at $4.80 and pre-funded warrants for 2,584,239 shares at $4.7999.","Led by Suvretta Capital, with Adage Capital, Nantahala Capital, and other healthcare-focused funds participating.","Proceeds to fund BB-301 clinical development (natural history lead-in and Phase 1b/2a treatment study) and general corporate purposes.","Kishen Mehta, portfolio manager at Suvretta, to be considered for board appointment.","Closing expected by April 22, 2024; Leerink Partners and Citizens JMP acting as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229830,"accession_number":"0001193125-24-100080","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Benitec reports positive interim clinical data for BB-301 in OPMD first subject at 90 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First subject showed improvements in videofluoroscopic swallowing studies and Sydney Swallow Questionnaire at Day 90 vs. pre-dose baseline.","No serious adverse events observed; two subjects had transient Grade 2 GERD that resolved with standard medication.","BB-301 is a gene therapy for OPMD, affecting ~15,000 patients worldwide; has FDA and EMA Orphan Drug designation.","Data from 90-day timepoint demonstrated improvement over initial natural history measurements taken >12 months prior."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248309,"accession_number":"0001193125-24-063667","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Benitec Biopharma grants 666,558 stock options to CEO and executive director at $5.21","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved nonqualified options for CEO Jerel Banks (466,554 shares) and Exec. Director Megan Boston (200,004 shares).","Exercise price of $5.21 per share equals March 6, 2024 closing price.","Options vest in three equal annual installments; full acceleration upon change in control.","Grants made under the Company's 2020 Equity and Incentive Compensation Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248308,"accession_number":"0001193125-24-032956","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Q2 net loss $6.8M; first BB-301 subject cleared DSMB review – enrollment continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.8M ($2.64 per share) for quarter ended Dec 31, 2023 vs $5.4M ($3.34) a year ago.","Cash and cash equivalents $20.4M at Dec 31, 2023, up from $2.5M at June 30, 2023.","First subject dosed with BB-301 in Nov 2023; DSMB review found no dose-limiting toxicities, recommended continuation without modifications.","23 subjects enrolled in OPMD natural history study; second subject scheduled to receive BB-301 in Feb 2024.","Interim safety and efficacy data from Phase 1b/2a Clinical Treatment Study expected mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265802,"accession_number":"0001193125-23-290709","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Benitec Biopharma stockholders approve all four proposals at 2023 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Edward Smith as director: 1,324,883 for, 54,894 withhold, 496,015 broker non-votes.","Ratification of independent auditor approved: 1,782,870 for, 57,064 against, 35,856 abstain.","Advisory vote on executive compensation approved: 1,327,852 for, 47,430 against, 4,493 abstain.","Amendment to 2020 Equity and Incentive Compensation Plan approved: 1,320,120 for, 56,877 against, 2,778 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265801,"accession_number":"0001193125-23-285671","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Benitec dosed first subject in Phase 1b/2a trial of BB-301 for OPMD dysphagia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BB-301 is a gene therapy candidate using Silence and Replace ddRNAi platform for Oculopharyngeal Muscular Dystrophy (OPMD).","OPMD affects ~15,000 patients in US, Canada, Western Europe, and Israel; no approved therapies currently exist.","Interim safety and efficacy data from the 52-week study expected in mid-2024.","19 subjects in the ongoing OPMD Natural History study are eligible to roll over into the BB-301 treatment study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265800,"accession_number":"0001193125-23-275384","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Biopharma Q1 net loss $6M; 19 OPMD subjects enrolled; BB-301 dosing expected Dec/Jan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.0M ($2.76 per share) vs $5.1M ($7.98 per share) in Q1 FY2023; higher share count reduced per-share loss.","Cash and equivalents $25.9M at Sep 30, 2023, up from $2.5M at Jun 30, 2023, extending runway.","R&D expense $4.4M (up 66% YoY) driven by BB-301 clinical development; G&A $1.6M (down 19% YoY).","19 subjects enrolled in OPMD Natural History Study as of Oct 2023; first BB-301 dose planned Dec 2023 or Jan 2024.","FDA IND clearance received; Canadian REB submission completed; interim safety/efficacy data expected within 12 months of first dose."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265799,"accession_number":"0001193125-23-257001","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Benitec Biopharma approves $273K bonus for CEO and $117K for Executive Director","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Compensation Committee approved discretionary bonus of $273,000 for CEO Jerel Banks for FY 2023.","Executive Director Megan Boston awarded $116,928 (converted from AUD at ~0.64 USD/AUD).","Bonuses relate to performance during fiscal year ended June 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283027,"accession_number":"0001193125-23-245807","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Benitec Biopharma regains Nasdaq compliance with $28.6M equity offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained compliance with Nasdaq minimum stockholders' equity rule via $28.6M net proceeds from August 2023 offering.","As of June 30, 2023, stockholders' equity was below $2.5M requirement; offering resolved deficiency.","Offering included 875,949 common shares, 15,126,226 pre-funded warrants, and 16,002,175 common warrants at $1.93 per unit.","Nasdaq will continue to monitor compliance; non-compliance at next report could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283026,"accession_number":"0001193125-23-239127","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Biopharma reports FY2023 net loss of $19.6M; FDA cleared BB-301 IND; completed $30.9M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.6M ($14.12/share) vs $18.2M ($37.88/share) prior year; cash $2.5M at June 30, 2023.","FDA cleared IND for BB-301 for OPMD in June 2023; 15 subjects enrolled in Natural History Study as of September.","Closed $30.9M public offering in August 2023 to fund BB-301 clinical development and operations.","R&D expenses $12.8M (up from $11.3M); expect to dose first BB-301 patient in 2H2023 with interim data in 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283025,"accession_number":"0001193125-23-237014","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Benitec Biopharma increases CEO base salary to $655,200, Executive Director to $350,784","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jerel Banks' (CEO) base salary raised to $655,200, effective Oct 1, 2023.","Megan Boston's (Executive Director) base salary raised to $350,784 (AUD converted at 0.64 USD/AUD), effective Oct 1, 2023.","Salary increases approved by Compensation Committee on September 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283024,"accession_number":"0001193125-23-210679","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Benitec Biopharma raises ~$30.9M gross in underwritten public offering; Series 2 warrants exercise price reset to $1.93","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering included 875,949 common shares, 15.1M pre-funded warrants, 16.0M common warrants; net proceeds ~$28.3M.","Combined purchase price $1.93 per share/warrant unit; common warrants exercisable at $3.86 for 5 years.","Exercise price of 29.8M outstanding Series 2 warrants automatically reset from $11.22 to $1.93 due to offering.","Proceeds to support clinical development of BB-301 (Phase 1b/2a natural history and treatment studies) and other programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283023,"accession_number":"0001193125-23-209112","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Benitec Biopharma regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 9, 2023, confirming compliance with Bid Price Rule 5550(a)(2).","Compliance achieved after closing price at $1.00/share or higher for 10 consecutive trading days.","Original deficiency notice was received on Sep 6, 2022, for bid price below $1.00 for 30 days.","Nasdaq has closed the matter; no further action required from the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283022,"accession_number":"0001193125-23-193295","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["3.03","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Benitec Biopharma effects 1-for-17 reverse stock split to meet Nasdaq minimum bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of common stock at 1-for-17 ratio effective July 26, 2023 at 12:01 a.m. ET.","Intended to bring company into compliance with Nasdaq $1.00 minimum bid price requirement for continued listing.","No fractional shares issued; all fractional shares rounded up to nearest whole share.","CUSIP changes to 08205P209; trading symbol BNTC remains unchanged.","Stockholders need not take action; Computershare acts as exchange agent for the split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302403,"accession_number":"0001193125-23-174479","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Benitec Biopharma receives FDA IND clearance for BB-301 gene therapy for OPMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for BB-301, a silence-and-replace gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD).","OPMD affects ~15,000 patients in US, Canada, Western Europe, and Israel; no approved therapies currently.","First subject dosing expected in H2 2023 after rollover from ongoing Natural History study (13 subjects enrolled).","Interim safety and efficacy data from Phase 1b/2a study to be reported every ~90 days post-dosing.","BB-301 designed to treat OPMD-related dysphagia, a life-threatening swallowing disorder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302402,"accession_number":"0001193125-23-167929","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Benitec Biopharma grants 356,900 options to CEO and 153,000 to Exec Director at $0.23/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Dr. Jerel Banks granted nonqualified stock options for 356,900 shares at $0.23 per share.","Executive Director Megan Boston granted nonqualified stock options for 153,000 shares at $0.23 per share.","Options vest in three equal annual installments, subject to continued service through each vesting date.","Unvested options fully accelerate upon a Change in Control as defined in the 2020 Equity Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302401,"accession_number":"0001193125-23-144217","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Q3 net loss $4.4M; 9 subjects enrolled in OPMD study; on track for BB-301 dosing in 2H2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.4M ($0.16/shr) in Q3 2023 vs $3.3M ($0.40/shr) in Q3 2022; cash $6.6M at Mar 31, 2023.","9 subjects enrolled in OPMD Natural History Study in the U.S.; pace supports BB-301 dosing and interim data disclosure in 2H2023.","R&D expenses $3.17M vs $2.17M YoY, driven by GMP manufacturing and Natural History Study; operating loss $4.4M.","Expects FDA IND response for BB-301 in Q2 2023; Canadian site activation pending REB approval.","CEO Jerel Banks to present at OPMD International Conference in Tel Aviv on May 16, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":68000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322058,"accession_number":"0001193125-23-064582","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Benitec Biopharma gets Nasdaq extension to Sept 5, 2023 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted Benitec an additional 180-day period until Sept 5, 2023 to meet the $1.00 minimum bid price rule.","Company failed to cure the bid price deficiency by the original deadline of March 6, 2023.","Compliance requires closing bid price of at least $1.00 for 10 consecutive business days during extension.","If not compliant by Sept 5, 2023, Nasdaq will begin delisting; Benitec may appeal to a hearings panel.","Benitec may consider a reverse stock split as a potential cure for the bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322057,"accession_number":"0001193125-23-034348","cik":1808898,"company_name":"Benitec Biopharma Inc.","ticker":"BNTC","form_type":"8-K","filed_at":"2023-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Benitec Biopharma Q2 net loss $5.4M; cash $10.5M; first OPMD patient enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.4M ($0.20/share) vs $4.8M ($0.59/share) in Q2 2022; revenue $14K.","Cash and cash equivalents $10.5M at Dec 31, 2022, up from $4.1M at June 30, 2022.","First patient enrolled in OPMD natural history study in Jan 2023; part of BB-301 program.","Expects IND/CTA clearance in Q2 2023; first BB-301 dosing anticipated in Q3 2023.","R&D expenses $3.8M, up $0.7M YoY due to toxicology and manufacturing projects."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":14000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":397823221.262069,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-13T23:59:59+00:00|322057"}